Ascendis Pharma A/S (ASND) Executive Compensation
Ascendis Pharma A/S (ASND) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ASND
CIK: 1612042
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: G7
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte Statsautoriseret Revisionspartnerselskab
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerRie Larsen
Audit LocationCopenhagen, Denmark
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 6-K | 2026-10-16 | 2026-10-16 | 6-K | 0001193125-26-423938 | View SEC Doc Filr Page |
| 6-K | 2026-10-14 | 2026-10-14 | 6-K | 0001193125-26-421789 | View SEC Doc Filr Page |
| 6-K | 2026-09-29 | 2026-09-29 | 6-K | 0001193125-26-407293 | View SEC Doc Filr Page |
| 4 | 2026-09-28 | 2026-04-14 | FORM 4 | 0001610717-26-000423 | View SEC Doc Filr Page |
| 6-K | 2026-09-15 | 2026-09-14 | 6-K | 0001193125-26-390877 | View SEC Doc Filr Page |
| 6-K | 2026-09-15 | 2026-09-14 | 6-K | 0001193125-26-390874 | View SEC Doc Filr Page |
| 6-K | 2026-09-09 | 2026-09-09 | 6-K | 0001193125-26-386630 | View SEC Doc Filr Page |
| 4 | 2026-09-09 | 2026-09-08 | FORM 4 | 0001610717-26-000409 | View SEC Doc Filr Page |
| 6-K | 2026-09-09 | 2026-09-09 | 6-K | 0001193125-26-386434 | View SEC Doc Filr Page |
| 144 | 2026-09-08 | — | 144 Filing | 0001964306-26-000432 | View SEC Doc Filr Page |
| 4 | 2026-09-03 | 2026-09-02 | FORM 4 | 0001610717-26-000395 | View SEC Doc Filr Page |
| 144 | 2026-09-02 | — | 144 Filing | 0001973379-26-000330 | View SEC Doc Filr Page |
| 6-K | 2026-08-31 | 2026-08-31 | 6-K | 0001193125-26-376733 | View SEC Doc Filr Page |
| 4 | 2026-08-18 | 2026-08-14 | FORM 4 | 0001610717-26-000360 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0001193125-26-349304 | View SEC Doc Filr Page |
| 6-K | 2026-08-13 | 2026-08-13 | 6-K | 0001193125-26-348046 | View SEC Doc Filr Page |
| 6-K | 2026-08-13 | 2026-06-30 | 6-K | 0001612042-26-000016 | View SEC Doc Filr Page |
| 6-K | 2026-08-12 | 2026-08-12 | 6-K | 0001193125-26-347172 | View SEC Doc Filr Page |
| 6-K | 2026-08-06 | 2026-08-06 | 6-K | 0001193125-26-337270 | View SEC Doc Filr Page |
| 6-K | 2026-07-15 | 2026-07-15 | 6-K | 0001193125-26-304903 | View SEC Doc Filr Page |
| 6-K | 2026-06-30 | 2026-06-30 | 6-K | 0001193125-26-290485 | View SEC Doc Filr Page |
| 6-K | 2026-06-29 | 2026-06-29 | 6-K | 0001193125-26-288414 | View SEC Doc Filr Page |
| 6-K | 2026-06-17 | 2026-06-17 | 6-K | 0001193125-26-274306 | View SEC Doc Filr Page |
| 6-K | 2026-06-15 | 2026-06-15 | 6-K | 0001193125-26-270227 | View SEC Doc Filr Page |
| 6-K | 2026-06-12 | 2026-06-12 | 6-K | 0001193125-26-268415 | View SEC Doc Filr Page |